{"entity":{"id":"paper-murray-nat-rev-cancer","kind":"paper","name":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","aka":[],"tldr":"Paper cited by one pathway page, indexed on Europe PMC as PubMed record 25568920 and published in Nature Reviews Cancer; the citing page links this DOI, which is how the record was matched.","summary":"The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as ‘dioxin’. AHR influences the major stages of tumorigenesis, initiation, promotion, progression and metastasis, and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.\n\nIndexed on Europe PMC as PubMed record 25568920 (DOI 10.1038/nrc3846). Matched by DOI alone: one pathway page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nat Rev Cancer 2014","url":"https://doi.org/10.1038/nrc3846"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/25568920/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/25568920"}],"tags":["europepmc-ingest"],"related":["chemical-carcinogenesis-receptor-activation"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-cancer"],"dependsOn":[],"notes":[],"journal":"Nature Reviews Cancer","year":2014,"doi":"10.1038/nrc3846","pmid":"25568920","authors":"Murray IA, Patterson AD, Perdew GH","paperType":"review","findings":[],"whatItMeans":"One pathway page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-murray-nat-rev-cancer/","neighbours":{"pathway":[{"id":"chemical-carcinogenesis-receptor-activation","kind":"pathway","name":"Chemical carcinogenesis - receptor activation","route":"/pathways/chemical-carcinogenesis-receptor-activation/"}],"journal":[{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/"}]}}